FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
0.9300
-0.0800 (-7.92%)
At close: Jun 9, 2026, 4:00 PM EDT
0.9490
+0.0190 (2.04%)
After-hours: Jun 9, 2026, 6:30 PM EDT
FibroBiologics Employees
FibroBiologics had 15 employees as of December 31, 2025. The number of employees increased by 2 or 15.38% compared to the previous year.
Employees
15
Change (1Y)
2
Growth (1Y)
15.38%
Revenue / Employee
n/a
Profits / Employee
-$1,245,333
Market Cap
5.02M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | 2 | 15.38% |
| Dec 31, 2024 | 13 | 3 | 30.00% |
| Dec 31, 2023 | 10 | 3 | 42.86% |
| Sep 30, 2023 | 8 | 1 | 14.29% |
| Jun 30, 2023 | 7 | - | - |
| Dec 31, 2022 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| BioAtla | 41 |
| CollPlant Biotechnologies | 39 |
| Aptevo Therapeutics | 33 |
| Cardio Diagnostics Holdings | 17 |
| TransCode Therapeutics | 12 |
| XTL Biopharmaceuticals | 10 |
| Mustang Bio | 4 |
FBLG News
- 6 days ago - FibroBiologics doses first patients in CYWC628 trial - TheFly
- 6 days ago - FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers - GlobeNewsWire
- 18 days ago - FibroBiologics presents preclinical data from CYPS317 program - TheFly
- 18 days ago - FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting - GlobeNewsWire
- 22 days ago - FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics - GlobeNewsWire
- 4 weeks ago - FibroBiologics expands fibroblast-based platform to target Hantavirus - TheFly
- 4 weeks ago - FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus - GlobeNewsWire
- 5 weeks ago - FibroBiologics CEO Issues Letter to Shareholders - GlobeNewsWire